Taxus Cardium Reports First Quarter 2014 Financial Results And Recent Developments

As recently announced, our Cardium Therapeutics operating unit is focused on the clinical and commercial development of advanced regenerative therapeutics that includes the GenerxA [Ad5FGF-4] product candidate, and ExcellagenA an FDA-cleared advanced wound care skin substitute product.

http://ift.tt/1gJ8iCA